Botros S S, Doughty B L, Shaker Z A, Akl M M, Sharmy R, Diab T M, Hassanein H I
Department of Immunology, Theodor Bilharz Research Institute, Guiza, Egypt.
Int J Immunopharmacol. 1996 Dec;18(12):707-18. doi: 10.1016/s0192-0561(97)85553-1.
This study was undertaken to study the efficacy of praziquantel (PZQ) in potentially tolerized Schistosoma mansoni infected, egg-injected C57BL/6 mice, receiving multiple administrations of soluble egg antigen (SEA) intravenously (i.v.). Four animal groups were studied. Experimental group I received four injections of SEA (10 micrograms) intravenously on days -7, -5, -3 and -2 before infection and PZQ orally (500 mg/kg over two consecutive days 7 weeks post-infection. Three control groups received the following treatment: group II received the same tolerizing dose of SEA without PZQ, group III received PZQ in the same dose and at the same timing. Group IV received S. mansoni infection and egg injection 8 weeks post-infection and served as an infected, egg-injected control. Egg injection was conducted 8 weeks post-infection using viable S. mansoni eggs via the tail vein. Animals were killed 16 days post-egg injection, i.e. 10 weeks post-infection. After sacrifice, lungs and livers were removed for histopathological study and measurement of granuloma diameters. Spleens and serum were collected for the assay of lymphoproliferative response to SEA and antischistosomal immunoglobulins. The worm and egg burdens were also studied. Compared to infected, egg-injected untreated controls, repeated i.v. administrations of SEA down-regulated egg-injected (pulmonary) and egg-deposited (hepatic) granulomas and the lymphoproliferative response to SEA. Antischistosomal IgG level was increased. Susceptibility to S. mansoni infection was not found to be different from that in the infected, egg-injected controls. PZQ in the dose used caused complete eradication of worms, disappearance of immature egg stages, decrease in the number of mature eggs and an increase in the number of dead eggs. Hepatic granuloma diameter, lymphoproliferative response to SEA and IgG level were reduced. In mice receiving a combined regimen of multiple SEA administrations and PZQ with down-regulated granuloma and reduced lymphoproliferative response to SEA, the efficacy of PZQ was the same as in mice receiving PZQ alone. This was shown by comparable grades of worm and egg reduction. The histopathological examination of liver and lung sections in the different treated groups revealed moderate to small-sized hypocellular granulomas. Although no statistically significant difference was recorded between the mean granuloma diameters of the experimental group receiving both the tolerizing dose of SEA and PZQ compared to the group receiving the tolerizing dose of SEA without chemotherapy, this experimental group showed the least associated histopathological parenchymal changes. It appears from this work that combined SEA and PZQ provided many complementary goals; a reduction of egg-induced pathology, minimal parenchymal changes and the eradication of worms.
本研究旨在探讨吡喹酮(PZQ)对经静脉多次注射可溶性虫卵抗原(SEA)诱导潜在免疫耐受的曼氏血吸虫感染且注射虫卵的C57BL/6小鼠的疗效。研究了四个动物组。实验组I在感染前第-7、-5、-3和-2天静脉注射四次SEA(10微克),并在感染后7周连续两天口服PZQ(500毫克/千克)。三个对照组接受以下处理:II组接受相同剂量的SEA诱导免疫耐受但不给予PZQ;III组在相同时间给予相同剂量的PZQ;IV组在感染后8周感染曼氏血吸虫并注射虫卵,作为感染且注射虫卵的对照。感染后8周经尾静脉注射活的曼氏血吸虫虫卵进行虫卵注射。在虫卵注射后16天(即感染后10周)处死动物。处死后,取出肺和肝脏进行组织病理学研究并测量肉芽肿直径。收集脾脏和血清用于检测对SEA的淋巴细胞增殖反应和抗血吸虫免疫球蛋白。还研究了虫体和虫卵负荷。与感染且注射虫卵但未治疗的对照组相比,多次静脉注射SEA可下调注射虫卵(肺部)和沉积虫卵(肝脏)引起的肉芽肿以及对SEA的淋巴细胞增殖反应。抗血吸虫IgG水平升高。未发现对曼氏血吸虫感染的易感性与感染且注射虫卵的对照组有差异。所用剂量的PZQ可完全清除虫体,使未成熟虫卵阶段消失,成熟虫卵数量减少,死卵数量增加。肝脏肉芽肿直径、对SEA的淋巴细胞增殖反应和IgG水平降低。在接受多次SEA注射和PZQ联合方案且肉芽肿下调和对SEA的淋巴细胞增殖反应降低的小鼠中,PZQ的疗效与单独接受PZQ的小鼠相同。虫体和虫卵减少程度相当表明了这一点。不同处理组肝脏和肺组织切片的组织病理学检查显示为中度至小尺寸的细胞减少性肉芽肿。虽然接受SEA诱导免疫耐受剂量和PZQ的实验组与接受SEA诱导免疫耐受剂量但未化疗的组之间,平均肉芽肿直径无统计学显著差异,但该实验组相关的组织病理学实质变化最少。从这项研究看来,SEA和PZQ联合使用实现了许多互补目标;减少虫卵诱导的病理变化、使实质变化最小化并清除虫体。